Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction

Centessa Pharmaceuticals plc

Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.
No thromboembolic events or treatment-related sustained D-dimer elevations observed.
Total target joints reduced by 94% (from 53 to 3) by end of Part 5.
Registrational PRESent-2 and PRESent-3 studies for hemophilia B are ongoing.
No SerpinPC-related adverse events reported in Part 5; favorable safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.